Table 5.
Results of Univariate Analyses of Overall Survival (OS) Time
| Variable | n | Mean OS (Months) | Log-Rank | p value |
|---|---|---|---|---|
| NCAPH | 4.402 | 0.036 | ||
| Negative | 58 | 67.33±11.99 | ||
| Positive | 95 | 38.51±17.67 | ||
| AGGF1 | 5.796 | 0.016 | ||
| Negative | 51 | 66.55±12.5 | ||
| Positive | 102 | 40.87±19.2 | ||
| FOXC2 | 73.712 | <0.001 | ||
| Negative | 71 | 64±15.31 | ||
| Positive | 82 | 36.82±16.83 | ||
| Age | 0.327 | 0.567 | ||
| <53 | 77 | 48.65±21.54 | ||
| ≥53 | 76 | 50.22±20.69 | ||
| Diameter | 0.529 | 0.467 | ||
| < 7cm | 95 | 49.49±22.63 | ||
| ≥ 7cm | 58 | 49.33±18.4 | ||
| Grade | 92.944 | <0.001 | ||
| HIgh-grade serous ovarian cancer | 69 | 66.17±12.89 | ||
| Low-grade serous ovarian cancer | 84 | 35.68±15.88 | ||
| FIGO stage | 92.234 | <0.001 | ||
| I-II | 63 | 68.14±10.01 | ||
| III-IV | 90 | 36.33±16.33 | ||
| LN metastesis | 44.906 | <0.001 | ||
| No | 106 | 57.15±18.35 | ||
| Yes | 47 | 32.02±15.84 | ||
| Ascite | 0.339 | 0.560 | ||
| No | 94 | 48.28±21.41 | ||
| Yes | 59 | 51.27±20.55 | ||
| Implantation | 32.766 | <0.001 | ||
| No | 96 | 57.77±18.96 | ||
| Yes | 57 | 35.39±16.57 |